Additionally, a nucleolin-targeted hollow silica nanoplatform developed for lymphoma therapy, co-loaded with doxorubicin and the sonosensitizer indocyanine green, with the surface functionalized with PEGylated AS1411 aptamer–lipid conjugates, selectively targeted lymphoma cells via nucleolin recognition [234]. This evidence concerns the gene NUCLEOLIN and lymphoma.